Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

LENZ Therapeutics (LENZ) EBIT (2022 - 2025)

LENZ Therapeutics (LENZ) has disclosed EBIT for 4 consecutive years, with -$38.5 million as the latest value for Q4 2025.

  • Quarterly EBIT fell 152.63% to -$38.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$91.1 million through Dec 2025, down 55.5% year-over-year, with the annual reading at -$91.1 million for FY2025, 55.5% down from the prior year.
  • EBIT for Q4 2025 was -$38.5 million at LENZ Therapeutics, down from -$18.9 million in the prior quarter.
  • The five-year high for EBIT was -$12.6 million in Q1 2023, with the low at -$38.5 million in Q4 2025.
  • Average EBIT over 4 years is -$20.2 million, with a median of -$16.9 million recorded in 2025.
  • The sharpest move saw EBIT soared 51.4% in 2023, then plummeted 152.63% in 2025.
  • Over 4 years, EBIT stood at -$26.8 million in 2022, then rose by 25.74% to -$19.9 million in 2023, then rose by 23.36% to -$15.2 million in 2024, then plummeted by 152.63% to -$38.5 million in 2025.
  • According to Business Quant data, EBIT over the past three periods came in at -$38.5 million, -$18.9 million, and -$16.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.